hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Healthcare Facilities & Services - NEC
- Sub-Industry: N/A
- Symbol: LON:HVO
- CUSIP: N/A
- Web: hvivo.com/
- Market Cap: £58.97 million
- Outstanding Shares: 78,101,000
- 50 Day Moving Avg: GBX 93.34
- 200 Day Moving Avg: GBX 133
- 52 Week Range: GBX 69.89 - GBX 239.75
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: £19.85 million
- Price / Sales: 2.97
- Book Value: GBX 0.59 per share
- Price / Book: 1.28
- EBIDTA: ($13,980,000.00)
- Net Margins: -73.08%
- Return on Equity: -32.75%
- Return on Assets: -25.48%
- Average Volume: 19,113 shs.
Frequently Asked Questions for Hvivo PLC (LON:HVO)
What is Hvivo PLC's stock symbol?
Hvivo PLC trades on the London Stock Exchange (LON) under the ticker symbol "HVO."
When will Hvivo PLC make its next earnings announcement?
Where is Hvivo PLC's stock going? Where will Hvivo PLC's stock price be in 2017?
1 analysts have issued 1 year target prices for Hvivo PLC's stock. Their predictions range from GBX 150 to GBX 150. On average, they anticipate Hvivo PLC's stock price to reach GBX 150 in the next year. View Analyst Ratings for Hvivo PLC.
Who are some of Hvivo PLC's key competitors?
Some companies that are related to Hvivo PLC include Summit Therapeutics PLC (SUMM), Oramed Pharmaceuticals (ORMP), Pfenex (PFNX), Ekf Diagnostics Holding PLC (EKF), Transenterix (TRXC), Transenterix (TRXC), MaxCyte (MXCT), Vernalis plc (VER), Lipocine (LPCN), Immunodiagnostic Systems Holdings PLC (IDH), Dicerna Pharmaceuticals (DRNA), Five Star Senior Living (FVE), Tissue Regenix Group PLC (TRX), VolitionRX Ltd (VNRX), Ergomed PLC (ERGO), Navidea Biopharmaceuticals (NAVB), Bovie Medical (BVX) and ImmuPharma PLC (IMM).
Who are Hvivo PLC's key executives?
Hvivo PLC's management team includes the folowing people:
- Kimberly Lynn Denny, Chief Executive Officer, Executive Director
- Graham Yeatman, Chief Financial Officer, Executive Director, Business Officer
- Jaime Wallace Ellertson, Non-Executive Chairman
- Trevor J. Nicholls Ph.D., Non-Executive Director
- Mark Robert Warne, Non-Executive Director
- James Francis Winschel Jr., Non-Executive Director
How do I buy Hvivo PLC stock?
Shares of Hvivo PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Hvivo PLC's stock price today?
MarketBeat Community Rating for Hvivo PLC (LON HVO)MarketBeat's community ratings are surveys of what our community members think about Hvivo PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Hvivo PLC stock can currently be purchased for approximately GBX 75.50.
Consensus Ratings for Hvivo PLC (LON:HVO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||GBX 150|
Analysts' Ratings History for Hvivo PLC (LON:HVO)
(Data available from 7/23/2015 forward)
|4/20/2017||Numis Securities Ltd||Reiterated Rating||Add||GBX 150|
Earnings History for Hvivo PLC (LON:HVO)Earnings History by Quarter for Hvivo PLC (LON HVO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Hvivo PLC (LON:HVO)
Current Year EPS Consensus Estimate: $-17.00 EPS
Dividend History for Hvivo PLC (LON:HVO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Hvivo PLC (LON:HVO)Insider Trades by Quarter for Hvivo PLC (LON:HVO)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/7/2017||Jaime Ellertson||Insider||Buy||16,888||GBX 89||£15,030.32|
|4/4/2017||Jaime Ellertson||Insider||Buy||12,508||GBX 128||£16,010.24|
|1/4/2017||Jaime Ellertson||Insider||Buy||10,114||GBX 161||£16,283.54|
|10/11/2016||James Winschel||Insider||Buy||2,221||GBX 180||£3,997.80|
|5/6/2015||James Winschel||Insider||Buy||8,000||GBX 321.60||£25,728|
|4/23/2015||James Winschel||Insider||Buy||12,350||GBX 330||£40,755|
Headline Trends for Hvivo PLC (LON:HVO)
Latest Headlines for Hvivo PLC (LON:HVO)
Hvivo PLC (HVO) Chart for Sunday, July, 23, 2017